Vectura Group (VEC) Stock Rating Reaffirmed by Peel Hunt

Share on StockTwits

Vectura Group (LON:VEC)‘s stock had its “hold” rating reiterated by stock analysts at Peel Hunt in a research report issued on Wednesday.

VEC has been the subject of a number of other reports. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a GBX 140 ($1.83) price target on shares of Vectura Group in a research note on Tuesday, August 21st. Shore Capital reiterated a “hold” rating on shares of Vectura Group in a research note on Tuesday, September 11th. Numis Securities reiterated a “buy” rating on shares of Vectura Group in a research note on Thursday, August 23rd. Royal Bank of Canada dropped their price target on Vectura Group from GBX 92 ($1.20) to GBX 88 ($1.15) and set a “sector performer” rating for the company in a research note on Wednesday, September 12th. Finally, Citigroup reiterated a “buy” rating and issued a GBX 155 ($2.03) price target on shares of Vectura Group in a research note on Monday, September 10th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Vectura Group has an average rating of “Buy” and an average price target of GBX 127.67 ($1.67).

Shares of VEC opened at GBX 71.05 ($0.93) on Wednesday. Vectura Group has a 52 week low of GBX 70 ($0.91) and a 52 week high of GBX 166.97 ($2.18).

About Vectura Group

Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.

Recommended Story: Intrinsic Value

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply